Oculis Stock Shock: Eye-Drop Trial Miss Sends Shares Sliding
Oculis Holding AG shares fell sharply on Friday after the Swiss eye-drug developer said two late-stage trials of its OCS-01 eye drops failed to meet their main goal in diabetic macular edema, a diabetes-linked swelling in the retina that can damage sight. The company said it does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug in that indication.
